The NTLA-2002 therapy shows promise for Type I and II HAE but has limited applicability for HAE with normal C1-INH (e.g., HAE-FXII), as the applicability of this drug to nC1-INH HAE depends on whether kallikrein overproduction plays a significant role in the pathophysiology. Here, SERPING1 is linked to hereditary angioedema.